AC-T Regimen | Semantic Scholar
BIG against BC on Twitter: "#APHINITYtrial is a phase III adjuvant study investigating the benefit of pertuzumab when added to trastuzumab + # chemotherapy #SABCS19 #OncoAlert https://t.co/AkL68wNO02" / Twitter
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. - Abstract - Europe
Myeloid Growth Factor Support for Dose-Dense Adjuvant Chemotherapy for Breast Cancer
Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis - The Journal of Thoracic and Cardiovascular Surgery
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet
BreastCancerUpdate.com - Clinical Trials
Chemotherapy for Uterus Cancer
Adjuvant chemotherapy of breast cancer
HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review
Progress of patients through the study. AC-DOC, sequential schedule of... | Download Scientific Diagram
Effect of Number of Treatment Cycles of Adjuvant Chemotherapy on Clinical Outcomes | Research To Practice
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802) - Annals of Oncology
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial - The Lancet Regional Health – Western Pacific
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial | Nature Communications
AC Chemotherapy Regimen | Living Beyond Breast Cancer
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet
AC Chemotherapy Regimen (Doxorubicin + Cyclophosphamide) - PDF Free Download
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer -
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
